PepGen Inc. Faces Class Action Lawsuit: Important Info for Investors

Overview of PepGen Inc. Class Action

PepGen Inc., a biopharmaceutical company focused on RNA-targeted therapies, is currently under scrutiny due to allegations of securities fraud. Investors may be impacted by the pending class action lawsuit, which aims to recover losses incurred during the period between March 7, 2024, and March 3, 2025.

Background of the Case

The law firm Levi & Korsinsky has taken up the baton on behalf of aggrieved PepGen investors who participated in trading the company’s shares during the aforementioned period. The lawsuit allege that PepGen made several misleading statements about its lead product candidate, PGN-EDO51. It suggests that PepGen misrepresented the efficacy and safety of this therapeutic candidate, which was expected to undergo FDA scrutiny via the CONNECT2 study.

According to the complaints filed, the key allegations against PepGen include:
1. Misrepresentation of Efficacy: Investors allege that PepGen misled them into believing that PGN-EDO51 was both safe and effective, whereas clinical evidence suggested otherwise.
2. FDA Approval Challenges: It has been claimed that the CONNECT2 study was fraught with issues that could significantly hinder PepGen’s potential for obtaining FDA approval, contrary to what the company publicly stated.
3. Consequences of Misleading Statements: As a direct result of these misrepresentations, investors may see a halt in the CONNECT2 study. This crisis has led to overstated expectations regarding PGN-EDO51’s clinical and commercial success.

Importance of the Lead Plaintiff Role

Investors wishing to be at the forefront of this case must step forward by August 8, 2025, to seek designation as the lead plaintiff. Serving as a lead plaintiff can provide a more active role in the litigation process, including influencing decisions related to the case but is not a prerequisite to share in potential recovery. All members of the class may be entitled to compensation without needing to pay out-of-pocket costs.

Getting Involved

For PepGen investors, or anyone interested in obtaining further details about the case, it is advisable to reach out to the law firm Levi & Korsinsky. They are available for consultations and can guide potential class members through the application process. Communication can be established through the following channels:

- Email: [contact email]
- Phone: (212) 363-7500

In addition, more information can be found by visiting their website, which provides resources and updates regarding the ongoing litigation.

Levi & Korsinsky’s Expertise

Levi & Korsinsky has built a solid reputation over the last two decades, successfully securing substantial financial settlements for shareholders. They have been recognized as one of the top firms in the securities litigation landscape, often making it into the top echelons of ISS Securities Class Action Services’ annual reports.

Conclusion

As the developments regarding this class action lawsuit unfold, it is imperative that affected investors stay informed and act swiftly to protect their rights. The outcome of this case could have significant repercussions for PepGen, its investors, and the future of RNA-targeted therapies.

For anyone affected by the events surrounding PepGen Inc., taking action now is essential to ensure a voice in this ongoing litigation.